This article is more than 5 years old. Information may no longer be current.
VIDEO: ZUMA trials assess CAR T-cell therapy for lymphoma
Click Here to Manage Email Alerts
CHICAGO — At ASCO Annual Meeting, Frederick Lundry Locke, MD, program co-leader of immunology at Moffitt Cancer Center, spoke with HemOnc Today at ASCO Annual Meeting about two ZUMA trials.
The ZUMA-1 trial assessed a single infusion of axicabtagene ciloleucel (Yescarta; Kite/Gilead) — an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy — for patients with refractory large B-cell lymphoma.
“Among patients who had complete or partial response at 3 months, 80% remained in response at 1 year,” Locke said.
In the ZUMA-7 trial, researchers are assessing second-line CAR T-cell therapy among patients with diffuse large B-cell lymphoma. Trial enrollment is in progress.
Disclosure: Locke reports honoraria from Kite; a consultant/advisory role with Cellular Biomedicine Group; research funding from FORMA Therapeutics and Kite; and a patent for the dendritic cell survivin vaccine.